Review the experience: role of propranolol in infantile hemangioma (IHs) on pediatric patient
DOI:
https://doi.org/10.18203/2349-2902.isj20182770Keywords:
Infantile Hemangioma (IHs), Pediatric, PropranololAbstract
Background: Although not being licensed for the treatment of infantile hemangiomas (IHs) on pediatric patient 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications. The objective of the present study was to review the experience on pediatric patients with efficacy and adverse effects after use of oral propranolol treatment for IHs started before 5 weeks or after 5 months of age.
Methods: This was an observational study performed pediatric patients with IHs treated with oral propranolol at the department of pediatric surgery, Gandhi Medical College and Associated Kamla Nehru Hospital, Bhopal from Nov 2012-Nov 2014. Using a proforma, data was collected on dosing, efficacy and adverse effects.
Results: A total 40 patient of IHs from 2 months to 3yr were included in this study. The majority of patients were ≤6month of age 24 (60%) patient and 16 (40%) patients were >6month of age. Female 28 (70%) are more affected than male 12 (30%). The IHs most common lesion was 23 (57.5%) in head, face and nose region. No adverse effects were observed in our series; none of our patients had symptoms of hypoglycemia or hypotension. The patients with clinically significant more than 50% volume reduction were found in 26 (65%) patient and 25-50% volume reduction were found 14 (35%) patient after 5months long propranolol therapy for IHs.
Conclusions: In present study of patients propranolol 2mg\kg\day divided into two doses was a well-tolerated and effective treatment of IHs. Propranolol is clinically more effective treatment with no adverse effect and cost effective. The percentage of regression of size and color clearance was sufficient to justify the use of propranolol as the first line option for treatment of IHs.
References
1. McGee P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital. Ulster Med J. 2013;82(1):16-20.
HCUP net. Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/data/hcup. Accessed March 31, 2010.
Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118(3):882-7.
Frieden IJ, Drolet BA. Propranolol for infantile hemangiomas: promise, peril, pathogenesis. Pediatr Dermatol. 2009;26(5):642-4.
Loffler H, Kosel C, Cremer H, Kachel W. Die Propranolol-therapy in the treatment of problematic hemangiomas: A new standard therapy is announced (Propranolol therapy to treat problematic hemangiomas: a new standard therapy makes its debut). Dermatologists. 2009;60(12):1013-1016
Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a Research Workshop on Infantile Hemangiomas; 2005 April 7-9; Bethesda, Maryland, USA. Hoboken: Wiley- Blackwell; 2005.
Léauté-Labrèze C, de la Roque ED, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Eng J Med. 2008;358(24):2649-51.
Bagazgoitia, L, Torrelo A, Gutiérrez JC, Hernández-Martín A, Luna P, Gutiérrez M, Baño A, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011.28(2):108-14.
Manunza F, Syed S, Laquida B, Linward J, Kennedy H, Gholam K. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermat. 2010;162(2):466-8.
Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthetic Surg. 2011;64(4):445-51.
Zaher H, Rasheed H, Hegazy RA, Hegazy RA, Abdelhalim DM, et al. Oral propranolol: an effective, safe treatment for infantile hemangiomas. Eur J Dermatol. 2011;21(4):558-63.
Price CJ, Lattouf C, Baum B, McLeod M, Schachner LA, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147(12):1371-6.
Talaat AA, Elbasiouny MS, Elgendy DS, Elwakil TF. Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. J Pediatr Surg. 2012;47(4):707-14.
Bertrand J, Sammour R, Mccuaig C, Dubois J, Hatami A, Ondrejchak S, et al. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic. J Cutaneous Med Surg. 2012;16(2):115-21.
Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. In Seminars in cutaneous Med Surg. 2010;29(2):106-114. Frontline Medical Communications.
Zvulunov A, McCuaig C, Frieden IJ, Mancini AJ, Puttgen KB, Dohil M, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011;28(2):94-8.
Schupp CJ, Kleber JB, Günther P, Holland‐Cunz S. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol. 2011;28(6):640-4.
Celik, S. Tiryaki,A. Musayev. Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers. J Drugs Dermatol. 2012;11:808-11.
Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatri. 2009124(3):e423-31.
Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26(5):610-4.
Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 20101;120(4):676-81.
Fraley DS, Bruns FJ, Segel DP, Adler S. Propranolol-related bronchospasm in patients without history of asthma. Southern Med J. 1980;73(2):238-40.
Pandey A, Gangopadhyay AN, Gopal SC, Kumar V, Sharma SP, Gupta DK, et al. Twenty years' experience of steroids in infantile hemangioma-a developing country's perspective. Journal of Pediatr Surg. 2009;44(4):688-94.
